Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two ... Read More
Vedanta Biosciences secures $27m to propel microbiome drug pipeline
US-based Vedanta Biosciences has raised $27 million in a Series C financing round to accelerate its pioneering work on microbiome-derived therapeutics. The funding round attracted ... Read More
Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment
Galecto Biotech, a Denmark-based pharmaceutical company specializing in galectin modulators for severe diseases like idiopathic pulmonary fibrosis (IPF) and cancer, has successfully raised €79 million ... Read More
Bristol-Myers Squibb’s Opdivo fails to meet key endpoint in small cell lung cancer trial
Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate -331 trial, designed to assess its effectiveness ... Read More
Bristol-Myers Squibb partners with Compugen to trial COM701 and Opdivo combination for advanced solid tumors
Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining its leading cancer drug Opdivo (nivolumab) with ... Read More